Orum Therapeutics, Inc. (KOSDAQ:475830)
25,350
+450 (1.81%)
Aug 14, 2025, 3:30 PM KST
Orum Therapeutics Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 |
---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 7,438 | 19,700 | 126,658 | 11,276 |
Short-Term Investments | 151,016 | 99,099 | - | - |
Trading Asset Securities | - | - | - | 809.55 |
Cash & Short-Term Investments | 158,454 | 118,799 | 126,658 | 12,085 |
Cash Growth | 25.10% | -6.21% | 948.05% | - |
Accounts Receivable | 2.95 | 2.48 | 0.6 | - |
Other Receivables | 452.53 | 2,530 | 492.53 | 38.37 |
Receivables | 455.48 | 2,532 | 493.14 | 38.37 |
Prepaid Expenses | 1,094 | 966.55 | 254.5 | 460.26 |
Other Current Assets | 687.87 | 212.88 | 41.83 | 72.42 |
Total Current Assets | 160,691 | 122,510 | 127,448 | 12,656 |
Property, Plant & Equipment | 29,103 | 30,610 | 32,370 | 5,184 |
Long-Term Investments | 44 | 44.1 | 12.87 | 2,552 |
Long-Term Deferred Tax Assets | 595.65 | 597.08 | 974.69 | 543.48 |
Other Long-Term Assets | 1,082 | 74.48 | 977.7 | 346.91 |
Total Assets | 191,515 | 153,836 | 161,783 | 21,283 |
Accounts Payable | 170.72 | - | 3.45 | 839.48 |
Accrued Expenses | 1,553 | 2,079 | 5,138 | 4,932 |
Short-Term Debt | - | - | - | 208.32 |
Current Portion of Leases | 2,745 | 28,122 | 2,572 | 845.64 |
Current Income Taxes Payable | - | - | 217.72 | 462.26 |
Other Current Liabilities | 1,203 | 1,663 | 1,207 | 1,633 |
Total Current Liabilities | 5,672 | 31,864 | 9,137 | 8,920 |
Long-Term Debt | - | - | - | 937.44 |
Long-Term Leases | 23,953 | 207.75 | 23,308 | 597.78 |
Other Long-Term Liabilities | 102.03 | 0 | 138.26 | 136.6 |
Total Liabilities | 29,727 | 32,071 | 32,583 | 10,592 |
Common Stock | 2,093 | 1,843 | 460 | 115 |
Additional Paid-In Capital | 226,986 | 179,471 | 690 | 1,035 |
Retained Earnings | -78,414 | -69,813 | -64,072 | -132,290 |
Comprehensive Income & Other | 11,124 | 10,263 | 6,743 | 3,678 |
Total Common Equity | 161,789 | 121,765 | -56,180 | -127,461 |
Shareholders' Equity | 161,789 | 121,765 | 129,200 | 10,691 |
Total Liabilities & Equity | 191,515 | 153,836 | 161,783 | 21,283 |
Total Debt | 26,698 | 28,330 | 25,879 | 2,589 |
Net Cash (Debt) | 131,756 | 90,469 | 100,779 | 9,496 |
Net Cash Growth | 30.74% | -10.23% | 961.28% | - |
Net Cash Per Share | 7586.75 | 4999.13 | 6693.64 | 2064.33 |
Filing Date Shares Outstanding | 20.93 | 18.43 | 4.6 | 1.15 |
Total Common Shares Outstanding | 20.93 | 18.43 | 4.6 | 1.15 |
Working Capital | 155,020 | 90,647 | 118,310 | 3,736 |
Book Value Per Share | 7728.98 | 6607.19 | -12212.99 | -110835.99 |
Tangible Book Value | 161,789 | 121,765 | -56,180 | -127,461 |
Tangible Book Value Per Share | 7728.98 | 6607.19 | -12212.99 | -110835.99 |
Land | - | - | - | 1,591 |
Machinery | 1,663 | 1,497 | 1,396 | 1,406 |
Construction In Progress | - | 36 | - | 445.16 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.